HK1139861A1 - Pde7 inhibitors for use in the treatment of movement disorders 7(pde7) - Google Patents

Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)

Info

Publication number
HK1139861A1
HK1139861A1 HK10106488.4A HK10106488A HK1139861A1 HK 1139861 A1 HK1139861 A1 HK 1139861A1 HK 10106488 A HK10106488 A HK 10106488A HK 1139861 A1 HK1139861 A1 HK 1139861A1
Authority
HK
Hong Kong
Prior art keywords
pde7
treatment
movement disorders
inhibitors
pde7 inhibitors
Prior art date
Application number
HK10106488.4A
Other languages
English (en)
Chinese (zh)
Inventor
John E Bergmann
Neil S Cutshall
Gregory A Demopulos
Vincent A Florio
George Gaitanaris
Patrick Gray
John Hohmann
Rene Onrust
Hongkui Zeng
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of HK1139861A1 publication Critical patent/HK1139861A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK10106488.4A 2007-03-27 2010-07-05 Pde7 inhibitors for use in the treatment of movement disorders 7(pde7) HK1139861A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92049607P 2007-03-27 2007-03-27
PCT/US2008/058530 WO2008119057A2 (en) 2007-03-27 2008-03-27 The use of pde7 inhibitors for the treatment of movement disorders

Publications (1)

Publication Number Publication Date
HK1139861A1 true HK1139861A1 (en) 2010-09-30

Family

ID=39789284

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10106488.4A HK1139861A1 (en) 2007-03-27 2010-07-05 Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)

Country Status (13)

Country Link
US (3) US20080260643A1 (xx)
EP (1) EP2139475B1 (xx)
JP (2) JP5580192B2 (xx)
CN (2) CN104758291B (xx)
AU (1) AU2008230710B2 (xx)
BR (1) BRPI0809244A2 (xx)
CA (1) CA2681650C (xx)
ES (1) ES2533206T3 (xx)
HK (1) HK1139861A1 (xx)
MX (1) MX2009010450A (xx)
NZ (1) NZ580413A (xx)
RU (1) RU2449790C2 (xx)
WO (1) WO2008119057A2 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
AU2010229144B2 (en) * 2009-03-23 2012-07-12 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944206B1 (fr) 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
AU2013202493B2 (en) * 2009-05-04 2016-03-10 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
ES2353093B1 (es) * 2009-05-20 2012-01-03 Consejo Superior De Investigaciones Científicas (Csic) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
ES2360783B1 (es) 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US20120115849A1 (en) 2010-11-08 2012-05-10 Demopulos Gregory A Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
CA2871151C (en) * 2012-05-07 2019-03-26 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
DK2846805T3 (en) * 2012-05-07 2019-03-18 Omeros Corp TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS
EP3505171A4 (en) * 2016-08-26 2020-08-26 Mitsubishi Tanabe Pharma Corporation BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND
CN112996492A (zh) * 2018-09-05 2021-06-18 阿姆斯特丹大学 Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US5932465A (en) * 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
CA2321224A1 (en) * 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
ATE371740T1 (de) * 1998-12-23 2007-09-15 Pfizer Phosphodiesterasen
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
US6627651B1 (en) 1999-05-07 2003-09-30 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
US6146876A (en) 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
US7491742B2 (en) * 1999-10-21 2009-02-17 Merck Patent Gmbh Imidazole derivatives as phosphodiesterase VII inhibitors
DE19950647A1 (de) 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
DE19953024A1 (de) * 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE19954707A1 (de) * 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
US6586478B2 (en) * 2000-02-22 2003-07-01 Cellegy Canada Methods and compositions for improving sleep
WO2001062904A1 (en) 2000-02-24 2001-08-30 Bayer Aktiengesellschaft Regulation of human gelatinase b-like enzyme 1
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
GB0015095D0 (en) 2000-06-20 2000-08-09 Celltech Chiroscience Ltd Chemical compounds
WO2002019213A2 (en) 2000-08-30 2002-03-07 Lilly Icos Llc Method for treatment of migraine using pde5 inhibitors
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
AU2954102A (en) 2000-11-14 2002-05-27 Byk Gulden Lomberg Chem Fab (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
AU2002224835A1 (en) 2000-11-14 2002-05-27 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Dihydroisoquinolines as novel phosphodiesterase inhibitors
IL140844A0 (en) * 2001-01-10 2002-02-10 Polygene Ltd Cationic polysaccharide compositions
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
US6617357B2 (en) 2001-03-06 2003-09-09 Smithkline Beecham Corporation Compounds and their use as PDE inhibitors
AP1699A (en) * 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1385843A1 (en) 2001-04-18 2004-02-04 Ortho-Mcneil Pharmaceutical, Inc. Arylindenopyridines with pde inhibiting activity
US6903109B2 (en) 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
US6958328B2 (en) 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EA200301100A1 (ru) 2001-04-25 2004-06-24 Алтана Фарма Аг Новые фталазиноны
US20030053980A1 (en) 2001-04-30 2003-03-20 The Gillette Company Shaving compositions containing highly lubricious water soluble polymers
WO2002088138A1 (en) 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PL367205A1 (en) * 2001-06-15 2005-02-21 Yamanouchi Pharmaceutical Co, Ltd. Phenylpyridine carbonyl piperazine derivative
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2002102313A2 (en) * 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US20030211040A1 (en) * 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
US20060286622A1 (en) * 2001-09-28 2006-12-21 Patricia Soulard Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity
DE60222931T2 (de) * 2001-12-13 2008-07-10 Asubio Pharma Co., Ltd. Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
WO2003057149A2 (en) 2001-12-28 2003-07-17 Bayer Corporation 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
US7378428B2 (en) * 2002-01-31 2008-05-27 Ono Pharmaceutical Co., Ltd. Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
US20040082061A1 (en) * 2002-02-14 2004-04-29 Anna Astromoff Drug metabolizing enzymes
EP1348433A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC Thiazol-2-yl-imine compounds as PDE-7 inhibitors
EP1348701A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP1608742A1 (en) 2002-11-13 2005-12-28 Bayer HealthCare AG DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b)
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US7217527B2 (en) * 2003-04-15 2007-05-15 Vanderbilt University Assay for phosphodiesterase function
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050130971A1 (en) * 2003-08-22 2005-06-16 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US7932250B2 (en) 2004-07-01 2011-04-26 Daiichi Sankyo Company, Limited Thienopyrazole derivative having PDE7 inhibitory activity
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
MX2007010721A (es) 2005-03-01 2007-11-13 Pfizer Ltd Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico.
CA2625153A1 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2631535C (en) * 2005-12-02 2010-07-27 Pfizer Limited Spirocyclic quinazoline derivatives as pde7 inhibitors
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders

Also Published As

Publication number Publication date
US20080260643A1 (en) 2008-10-23
RU2009138966A (ru) 2011-05-10
ES2533206T3 (es) 2015-04-08
AU2008230710A1 (en) 2008-10-02
US20110091388A1 (en) 2011-04-21
BRPI0809244A2 (pt) 2014-09-23
MX2009010450A (es) 2009-11-23
RU2449790C2 (ru) 2012-05-10
CA2681650C (en) 2016-11-22
WO2008119057A2 (en) 2008-10-02
AU2008230710B2 (en) 2014-04-10
CA2681650A1 (en) 2008-10-02
CN101917992A (zh) 2010-12-15
JP5943964B2 (ja) 2016-07-05
US20190183824A1 (en) 2019-06-20
JP5580192B2 (ja) 2014-08-27
EP2139475A4 (en) 2012-03-07
EP2139475A2 (en) 2010-01-06
JP2014198718A (ja) 2014-10-23
CN104758291A (zh) 2015-07-08
NZ580413A (en) 2012-11-30
JP2010522768A (ja) 2010-07-08
CN104758291B (zh) 2020-03-03
EP2139475B1 (en) 2014-12-17
WO2008119057A3 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
HK1139861A1 (en) Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
IL185485A0 (en) Use of pde7 inhibitors for the treatment of neuropathic pain
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
EP1874286A4 (en) METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL195152A (en) Compounds for use in treating diseases of cell culture
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HK1129426A1 (zh) 用於治療肺部病症的酶的合成物
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
EP2077838A4 (en) METHODS FOR TREATING A-RELATED DISORDERS AND COMPOSITIONS THEREFOR
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
EP2370087A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS
ZA200707147B (en) Use of PDE7 inhibitors for the treatment of neuropathic pain
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain